GEN Exclusives

More »

GEN News Highlights

More »
Jan 25, 2011

GenVec and NMRC Take On Dengue Fever Vaccine R&D

  • GenVec and the U.S. Naval Medical Research Center (NMRC) have entered into a CRADA to support NMRC’s dengue fever vaccine research. Under a separate contract with the Henry M. Jackson Foundation for the Advancement of Military Medicine, GenVec will receive funding for the development and preparation of vaccines related to this program.

    The company anticipates that it will recognize approximately $530,000 of revenue associated with the completion of work under the agreement with the Jackson Foundation, which is expected this year.

    GenVec will be responsible for designing and manufacturing candidates using its adenovector technology. The vaccines will be manufactured utilizing GenVec's cell line. NMRC will be responsible for preclinical animal studies including studies in nonhuman primates.

     


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?